TY  - JOUR
AU  - Möhrmann, Lino
AU  - Rostock, Lysann
AU  - Werner, Maximilian
AU  - Oleś, Małgorzata
AU  - Arnold, Jonas
AU  - Paramasivam, Nagarajan
AU  - Jöhrens, Korinna
AU  - Rupp, Luise
AU  - Schmitz, Marc
AU  - Richter, Daniela
AU  - Uhrig, Sebastian
AU  - Fröhlich, Martina Antonia
AU  - Hutter, Barbara
AU  - Hüllein, Jennifer
AU  - Jahn, Arne
AU  - Arlt, Marie
AU  - Möhrmann, Elena E
AU  - Hanf, Dorothea
AU  - Gieldon, Laura
AU  - Kreutzfeldt, Simon
AU  - Heilig, Christoph E
AU  - Teleanu, Maria-Veronica
AU  - Lipka, Daniel B
AU  - Beck, Katja
AU  - Baude-Müller, Annika
AU  - Mock, Andreas
AU  - Jelas, Ivan
AU  - Rieke, Damian T
AU  - Wiesweg, Marcel
AU  - Brandts, Christian
AU  - Boerries, Melanie
AU  - Illert, Anna L
AU  - Desuki, Alexander
AU  - Kindler, Thomas
AU  - Krackhardt, Angela M
AU  - Westphalen, C Benedikt
AU  - Christopoulos, Petros
AU  - Apostolidis, Leonidas
AU  - Stenzinger, Albrecht
AU  - Allgäuer, Michael
AU  - Neumann, Olaf
AU  - Kerle, Irina
AU  - Horak, Peter
AU  - Heining, Christoph
AU  - Grosch, Heidrun
AU  - Schröck, Evelin
AU  - Hübschmann, Daniel
AU  - Fröhling, Stefan
AU  - Glimm, Hanno
TI  - Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors.
JO  - Med
VL  - 6
IS  - 6
SN  - 2666-6340
CY  - Amsterdam
PB  - Elsevier
M1  - DKFZ-2025-00591
SP  - 100612
PY  - 2025
N1  - #LA:B340#LA:B280#LA:W015 / 2025 Jun 13;6(6):100612/ Computational Oncology Group (CO), Molecular Precision Oncology Program (MPOP), German Cancer Research Center (DKFZ), translational Functional Cancer Genomics, DKFZ Heidelberg, Heidelberg, Germany,  Innovation and Service Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany
AB  - Thymic epithelial tumors (TETs) are rare malignancies with limited treatment options and underexplored molecular features.We examined the genomic landscape and therapeutic outcomes in 81 patients with advanced TETs, including thymic carcinomas (TCs), thymomas, and thymic neuroendocrine neoplasms (TNENs), who were enrolled in the MASTER trial, a prospective observational precision oncology trial.Using whole-genome-sequencing and whole-exome-sequencing analysis, transcriptome analysis, and methylome analysis, we identified distinct molecular features across TET subtypes, including a higher tumor mutational burden in TC and pathogenic germline variants in 18
KW  - Translation to patients (Other)
KW  - molecular profiling (Other)
KW  - multiomics (Other)
KW  - precision oncology (Other)
KW  - prospective observational study (Other)
KW  - targeted therapy (Other)
KW  - thymic carcinoma (Other)
KW  - thymic epithelial tumor (Other)
KW  - thymic neuroendocrine neoplasm (Other)
KW  - thymoma (Other)
KW  - whole-genome sequencing (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40107270
DO  - DOI:10.1016/j.medj.2025.100612
UR  - https://inrepo02.dkfz.de/record/299861
ER  -